Arterial responses to infusion of Glucagon-like Peptide-1 in humans: A randomized trial study

Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12612 ◽

2016 ◽

Vol 18 (3) ◽

pp. 281-288 ◽

Cited By ~ 4

Author(s):

M. M. Smits ◽

L. Tonneijck ◽

M. H. A. Muskiet ◽

M. H. H. Kramer ◽

M. Diamant ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Trial ◽

Receptor Agonist ◽

Acute Effect ◽

Exocrine Pancreatic Function ◽

Pancreatic Function ◽

Glucagon Like Peptide ◽

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

Diabetes Obesity and Metabolism ◽

10.1111/dom.12937 ◽

2017 ◽

Vol 19 (7) ◽

pp. 1024-1031 ◽

Cited By ~ 57

Author(s):

Paolo Pozzilli ◽

Paul Norwood ◽

Esteban Jódar ◽

Melanie J. Davies ◽

Tibor Ivanyi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Randomized Trial ◽

Receptor Agonist ◽

Daily Insulin ◽

Glucagon Like Peptide ◽

Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518

Diabetes Care ◽

10.2337/dci21-0004 ◽

2021 ◽

Vol 44 (11) ◽

pp. e196-e197

Author(s):

Julio Rosenstock

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Diabetes Care ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518

Diabetes Care ◽

10.2337/dc20-2987 ◽

2021 ◽

Vol 44 (11) ◽

pp. e194-e195 ◽

Cited By ~ 1

Author(s):

Chinmay S. Marathe ◽

Karen L. Jones ◽

Christopher K. Rayner ◽

Tongzhi Wu ◽

Michael Horowitz

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Diabetes Care ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial

Diabetic Medicine ◽

10.1111/dme.12003 ◽

2012 ◽

Vol 30 (1) ◽

pp. 109-113 ◽

Cited By ~ 18

Author(s):

M. Nauck ◽

E. Horton ◽

M. Andjelkovic ◽

F. J. Ampudia-Blasco ◽

C. T. Parusel ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Randomized Trial ◽

Open Label ◽

Glucagon Like Peptide ◽

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Diabetes Care ◽

10.2337/dc19-2316 ◽

2020 ◽

Vol 43 (10) ◽

pp. 2509-2518 ◽

Cited By ~ 2

Author(s):

Julio Rosenstock ◽

Antonio Nino ◽

Joseph Soffer ◽

Lois Erskine ◽

Andre Acusta ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Receptor Agonist ◽

Prandial Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Faculty Opinions recommendation of Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738371721.793577217 ◽

2020 ◽

Author(s):

John Tayek

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Receptor Agonist ◽

Prandial Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Effects of glucagon-like peptide-1 (GLP-1) on gastric accommodation, emptying and satiety in humans

Gastroenterology ◽

10.1016/s0016-5085(01)80365-6 ◽

2001 ◽

Vol 120 (5) ◽

pp. A74-A74

Author(s):

S AROS ◽

D KIM ◽

D BURTON ◽

G THOMFORDE ◽

A VELLA ◽

...

Keyword(s):

Gastric Accommodation ◽

Glucagon Like Peptide ◽

Developmental changes in localization of glucagon-like peptide-1 in the rat's hippocampus

Neuroscience Research ◽

10.1016/s0168-0102(00)81199-2 ◽

2000 ◽

Vol 38 ◽

pp. S59

Author(s):

J Oka

Keyword(s):

Developmental Changes ◽

Glucagon Like Peptide ◽

Eine häufige genetische Variation in WFS1 bedingt eine gestörte Glucagon-like Peptide-1-induzierte Insulinsekretion

Diabetologie und Stoffwechsel ◽

10.1055/s-0029-1221858 ◽

2009 ◽

Vol 4 (S 01) ◽

Author(s):

K Müssig ◽

SA Schäfer ◽

H Staiger ◽

F Machicao ◽

N Stefan ◽

...

Keyword(s):

Genetische Variation ◽

Glucagon Like Peptide ◽